This study demonstrates the presence of PGI2 in blood and its influence on platelet retention tests, possibly by the intermediate of a releasing system in the columns, which is followed by a proximate recuperation on the erythrocyte sites after the passage.
The presence of prostacyclin on the erythrocyte sites seems to depend upon the red cell deformability in relation to the good condition of their erythrycote ATP reserve.
The load of the erythrocyte sites increases with the daily dose of dipyrida mole. The maximum load of the sites appears to be reached with a daily dose of dipyridamole 450mg.
Approximately 10% of the atherosclerosis patients who have been treated by dipyridamole keep their platelet hyperaggregability and their abnormally low ered prostacyclin level.
Get full access to this article
View all access options for this article.
References
1.
Solvay H., Kahn M., Selosse P., et al: Atherosclerosis and cerebral ischemic attacks: Intakes of cerebrography with xenon133 inhaled and platelet tests in the diagnosis and clinical and therapeutic monitoring; the preventive role of dipyridamole. Angiology3(11):709-717, 1984.
2.
Solvay H., Van Schepdael J: Evaluation clinique et biologique du traitement à long terme par le dipyridamole de 190 patients athéromateux. Ars Medici36:795-805, 1981.
3.
Solvay H., Kahn M.: Considérations à propos de la rétention plaquettaire sur billes de verre chez le patient athéromateux. Evaluation du rapport dose-réponse au dipyridamole. Acta Therapeutica7:275-282, 1981.
4.
Solvay H., Kahn M., Cloarec M., et al: Evaluation par le test de rétention plaquettaire sur sang total des variations post-prandiales de l'activité des thrombocytes: Incidences physiologiques, pathologiques, cliniques de ces variations et rôle du dipyridamole . Acta Therapeutica11:139-153, 1985.
5.
Neri Sernegi GG, Masotti G., Abbate R., et al: Enhanced prostacyclin production and decreased thromboxane formation by dipyridamole. Ed. Excerpta Medica Amsterdam1979. International Meeting on myocardial infarction, Florence, May 8-12, 1979.
6.
Siess W. and Dray F.: Very low levels of 6 keto-prostaglandin F1 in human plasma. J Lab Clin Med3:38, 1982.
7.
Willems CH, Van Aken WG, Van Mourik JA: Binding of prostacyclin (PGI2) to human erythrocytes. Acta Therapeutica6: 31, 1980.
8.
Bult H., Beetens J., Herman AG: Blood levels of 6-oxo PGF, alpha endotoxin induced hypotension in rabbits . Eur J Pharmacology63:47-56, 1980.
9.
Wynalda M. and Fitzpatrick FA: Prostaglandins. 20:853-683, 1980.
10.
Fitzpatrick FA and Wynalda MA: Albumin-lipid interactions: Prostaglandin stability as a probe for characterizing binding sites on vertebrate albumins . Biochemistry20:6129-6134, 1981 .
11.
Tsukada T.: Platelet retention in glass bead columns: Its mechanism and the effect of plasma proteins. Thrombosis Research8 S II:203, 1976.
12.
Reid HL, Dormandy JA, Barnes AJ and Dormandy TL: Impaired red cell deformability in peripheral vascular disease. Lancet1:666-668, 1976.
13.
Weed RI, La Celle PL and Mervill W: Metabolic dependence of red cell deformability . J Clin Invest48:795-809, 1969.
14.
Schatzmann HJ: The red cell calcium sums. Ann Rev Physiol45:303-312, 1983.
15.
Schatzmann HJ: ATP—Dependent CA2+ —Extrusion from human red cells. Experientia22:364-368, 1966.
16.
Richards DR , Rega AF and Garrahan PJ: Two classes of sites for ATP in the CA2 + —atpase from human red cell membranes. Biochim Biophys Acta511:194-201, 1978.
17.
Muallem S., Karlisch Sjd: Studies on the mechanism of regulation of the red cell CA2÷ —pump by calmodulin and ATP. Biochim Biophys Acta647:73-86, 1981.
18.
Garrahan PJ , Rega AF: Activation of partial reactions of the CA2÷ —atpase from human red cells by Mg2÷ and ATP. Biochim Biophys Acta513:59-65, 1978.
19.
Solvay H., Kahn M., Telerman M., et al: ATP—Mg Erythrocytaire, Hyperagrégabilité plaquettaire et action du dipyridamole a paraitre.
20.
Lew O., Tsien VL,RY and Miller C.: The physiological (CA2÷ )i—level and pump leak turnover in intact red cells measured with the use of an incorporated CAchelator. Nature298:478-481, 1982.
